Long-term follow-up after complete resection of well-differentiated cancer confined to the thyroid gland

Annals of Surgical Oncology

Volumn 16, Issue 10, 2009, Pages 2862-2874

  Vorburger, Stephan A ^a   Übersax, Lucia ^a   Schmid, Stefan W ^a   Balli, Mariette ^a   Candinas, Daniel ^a   Seiler, Christian A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DATA BASE; DEATH; DISEASE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERVIEW; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; RADIOIODIDE ABLATION; SUBTOTAL THYROIDECTOMY; SURVIVAL; THYROID CARCINOMA; WELL DIFFERENTIATED THYROID CARCINOMA; ADENOCARCINOMA; AGED; CANCER STAGING; CELL DIFFERENTIATION; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; THYROID TUMOR; THYROIDECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73349121349     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0592-4     Document Type: Article

References (50)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
2. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-11.
3. Lundgren CI, Hall P, Ekbom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differenti-ated thyroid cancer. Int J Cancer. 2003;106:569-73.
4. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79:564-73.
5. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically sig-nificant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106: 524-31.
6. Lang BH, Lo CY, Chan WF, Lam AK, Wan KY. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg. 2006;30:752-8.
7. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-85.
8. Lang B, Lo CY, Chan WF, Lam KY, Wan KY. Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. Ann Surg Oncol. 2007;14:1551-9.
9. Passler C, Prager G, Scheuba C, Kaserer K, Zettinig G, Niederle B. Application of staging systems for differentiated thyroid car-cinoma in an endemic goiter region with iodine substitution. Ann Surg. 2003;237:227-34.
10. Hay ID, Klee GG. Thyroid cancer diagnosis and management. Clin Lab Med. 1993;13:725-34.
11. Blankenship DR, Chin E, Terris DJ. Contemporary management of thyroid cancer. Am J Otolaryngol. 2005;26:249-60.
12. Mazzaferri EL. Long-term outcome of patients with differenti-ated thyroid carcinoma: effect of therapy. Endocr Pract. 2000;6:469-76.
13. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Green-span FS, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004;100:1123-9.
14. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986;61:978-96.
15. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V, Werber J. Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg. 1976;184:541-53.
16. Farrar WB, Cooperman M, James AG. Surgical management of papillary and follicular carcinoma of the thyroid. Ann Surg. 1980;192:701-4.
17. Starnes HF, Brooks DC, Pinkus GS, Brooks JR. Surgery for thyroid carcinoma. Cancer. 1985;55:1376-81.
18. Clark OH, Levin K, Zeng QH, Greenspan FS, Siperstein A. Thyroid cancer: the case for total thyroidectomy. Eur J Cancer Clin Oncol. 1988;24:305-13.
19. Gemsenjager E, Heitz PU, Martina B. Selective treatment of differentiatedthyroidcarcinoma. World J Surg. 1997;21:546-51; discussion 51-2.
20. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164:658-61.
21. Harness JK, Fung L, Thompson NW, Burney RE, McLeod MK. Total thyroidectomy: complications and technique. World J Surg. 1986;10:781-6.
22. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-81; discussion 81-4.
23. Schroder DM, Chambors A, France CJ. Operative strategy for thyroid cancer. Is total thyroidectomy worth the price? Cancer. 1986;58:2320-8.
24. Kebebew E, Clark OH. Differentiated thyroid cancer: "com-plete" rational approach. World J Surg. 2000;24:942-51.
25. Udelsman R, Shaha AR. Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer? Lancet Oncol. 2005;6:529-31.
26. Haigh PI, Urbach DR, Rotstein LE. AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States. Surgery. 2004;136:609-16.
27. Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg. 1998;227: 912-21.
28. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-42.
29. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low-or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81-9.
30. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol. 1997;4:328-33.
31. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622-7.
32. Mazzaferri EL. Papillary and follicular thyroid cancer: selective therapy. Compr Ther. 1981;7:6-14.
33. Greene F. AJCC cancer staging handbook: TNM classification of malignant tumors. 6th ed. New York: Springer/Verlag; 2002.
34. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958;1:457-71.
35. Therneau TM GP. Modeling survival data: Extending the Cox model. New York: Springer; 2000.
36. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol. 1996;3:534-8.
37. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007;14:730-8.
38. Schwab R, Wieler H, Birtel S, Ostwald-Lenz E, Kaiser KP, Becker HP. Confronting the practice of surgery on differentiated thyroid cancer with current guidelines in Germany. A multicenter trial. Nuklearmedizin. 2005;44:185-91.
39. Lerch H, Schober O, Kuwert T, Saur HB. Survival of differen-tiated thyroid carcinoma studied in 500 patients. J Clin Oncol. 1997;15:2067-75.
40. Steinmuller T, Klupp J, Rayes N, Ulrich F, Jonas S, Graf KJ, et al. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg. 2000;166:29-33.
41. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G, et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. EndocrRelat Cancer. 2004;11:131-9.
42. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16: 109-42
43. Taskforce TC AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma, 2001.
44. Seiler CA, Vorburger SA, Burgi U, Candinas D, Schmid SW. Extended resection for thyroid disease has less operative mor-bidity than limited resection. World J Surg. 2007;31:1005-13.
45. Bilimoria KY, Zanocco K, Sturgeon C. Impact of surgical treatment on outcomes for papillary thyroid cancer. Adv Surg. 2008;42:1-12.
46. Shah JP. Re: extent of surgery affects papillary thyroid cancer. Ann Surg. 2008;247:1082-3; author reply 83-4.
47. Rosenbluth BD, Serrano V, Happersett L, Shaha AR, Tuttle RM, Narayana A, et al. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys. 2005;63:1419-26.
48. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005; 63:418-27.
49. Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson JC, et al. External beam radiotherapy in the man-agement of differentiated thyroid cancer. Clin Oncol (R Coll Radiol). 2003;15:337-41.
50. Tuttle M, Robbins R, Larson SM, Strauss HW. Challenging cases in thyroid cancer: a multidisciplinary approach. Eur J Nucl Med Mol Imaging. 2004;31:605-12.